Compare ALS' cash flow story with a curated group of potential peers by scanning the 5 high quality undervalued stocks, which currently combines solid fundamentals with pricing that screens as attractive on Simply Wall St.
To own ALS today, you need to be comfortable that the current record profit base can hold up while the group keeps investing in technology, cyber security and lab automation. The short term swing factor is whether those digital projects lift throughput and keep geochemistry and PFAS heavy work running smoothly or simply add extra cost.
The biggest near term risk is that higher cyber and IT spending lingers after the recent incident without a clear offset in productivity, squeezing margins just as some Environmental operations already face integration challenges. If that spending profile turns out to be modest, the latest news does not fundamentally change the near term business story.
One of the most relevant recent developments is the malicious cyber incident that ALS has already disclosed. Management had to take containment actions, which can be disruptive for laboratories that rely on a unified LIMS platform covering most of group revenue, and that interruption risk matters for the cash flow debate.
Where this ties back to catalysts is straightforward. ALS is relying on a single LIMS system, internal AI tools and more automation to support productivity and quality. At the same time, the breach raises the likelihood of higher ongoing cyber costs or client scrutiny. The key question for investors is whether that extra security spend limits margin potential or supports more dependable earnings over time.
ALS' current consensus narrative points to A$4.1b revenue and A$536.0 million earnings by 2029. That profile implies 7.2% yearly revenue growth and an earnings increase of about A$217.3 million from A$318.7 million today.
Uncover why ALS' fair value indicates a 19% potential upside to its current price before that discount closes.
For ALS, the biggest alternate storyline is that rising Smart Lab, AI and cyber security spending simply eats into profitability. The most bearish analysts were already pencilling in A$4.0b revenue and about A$522.4 million earnings by 2029 before this incident. That is a more cautious script. Use it as a prompt to compare several viewpoints and reassess your own expectations.
Explore 2 other ALS fair value estimates, including one that suggests it could be worth just A$24.12.
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
If the ALS story has sharpened your thinking and you want to pressure test your thesis against other opportunities, the Simply Wall St Screener can help you quickly surface stocks with very different profiles to compare against this laboratory group.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com